Clinical trials: Neovascular Age-Related Macular Degeneration
- Condition Neovascular Age-Related Macular Degeneration
- Funder type Industry (pharma, biotech, devices)
Neovascular Age-related Macular Degeneration, Intermediate Age Related Macular Degeneration (Disorder)
Single In-Clinic Encounter With the Notal Vision Home OCT
this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of…
- Trial name
- NCT04642183
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Notal Vision Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME
To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
- Trial name
- NCT05698329
- Testing
- AIV007
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- AiViva BioPharma, Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
The goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration.
- Trial name
- NCT07489586
- Testing
- QL1207H injection, Aflibercept 8 mg
- Volunteers
- 356 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
- Trial name
- NCT01255462
- Testing
- LFG316
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- TORRONTES (NCT07496567)
- Testing
- Tiespectus, Aflibercept
- Where
- 71 sites in United States, Brazil and 7 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Age-Related Macular Degeneration
Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD
This study will evaluate the safety and preliminary effectiveness of PDS 1.0 in patients with neovascular AMD.
- Trial name
- NCT01177644
- Testing
- PDS 1.0
- Where
- Israel
- Sponsor
- Forsight Vision4
Neovascular (Wet) Age-Related Macular Degeneration
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile.
- Trial name
- NCT07557121
- Testing
- AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- AiViva BioPharma, Inc.
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with…
- Trial name
- NCT01997164
- Testing
- REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-Related Macular Degeneration
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD…
- Trial name
- RAZORBILL (NCT04662944)
- Testing
- brolucizumab, ranibizumab, aflibercept
- Where
- 17 sites in Canada, Germany and 3 more
- Volunteers
- 494 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question[s] it aims to answer are: Safety of the maximum tolerable dose of AXT107 Bioactivity and…
- Trial name
- DISCOVER (NCT05859776)
- Testing
- AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Age-Related Macular Degeneration
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal…
- Trial name
- NCT01089517
- Testing
- E10030 plus Lucentis, Lucentis
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Ophthotech Corporation